🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Toripalimab

    Coherus Oncology

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial

  2. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tracheal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Toripalimab+Nedaplatin+Albumin Paclitaxel

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Toripalimab-tpzi

    Coherus Oncology

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  6. Transplantation of Autologous stem cell [MNCs] .

    Hospital Authority, Hong Kong

    Spinal Cord Injury.

    phase 2 mab active

    1 trial

  7. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Trimeton 10 mg/1 ml soluzione iniettabile, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Gazyvaro 1,000 mg concentrate for solution for infusion., TACHIPIRINA 500 mg compresse, MEDROL 16 mg compresse, CORTRIUM 40 mg/2 ml polvere e solvente per soluzione iniettabile

    Istituto Gentili S.r.l.

    Primary Membranous Nephropathy

    phase 2 small molecule active

    1 trial

  9. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  10. UB-221

    United Therapeutics Europe Ltd

    Chronic Spontaneous Urticaria

    phase 2 mab active

    1 trial

  11. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  12. VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  13. VB10.NEO

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Solid Tumours

    phase 2 mab completed

    1 trial

  14. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

    phase 2 mab completed

    1 trial

  15. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  16. VT30

    BridgeBio Oncology Therapeutics

    Venous Malformation

    phase 2 small molecule terminated

    1 trial

  17. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule completed

    4 trials

  18. Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  19. Vedolizumab

    Takeda

    Collagenous Gastritis

    phase 2 mab active

    1 trial

  20. Vedolizumab intravenous injection

    Takeda

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  21. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Leukemia of Ambiguous Lineage

    phase 2 small molecule active

    1 trial

  22. Vipoglanstat, The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.

    Lacuna Pharma Pty Ltd

    Endometriosis related pain

    phase 2 small molecule active

    1 trial

  23. XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  24. Xarelto 2.5 mg film-coated tablets

    Tour Hekla

    Chronic hemodialysis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources